Clinical Trial Update: Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial investigating combined 18F-NaF/18F-FDG PET/MRI for detecting skeletal metastases in cancer patients; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• 18F-NaF/18F-FDG PET/MRI (combined imaging agents)

Snippet

Sponsor: Stanford University | Conditions: Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-11-08